Finanzen von Kewaunee Scientific Corp (KEQU)KEQUKewaunee Scientific Corp

Kewaunee Scientific Corp (KEQU) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Domestic, accounting for 73.4% of total sales, equivalent to $50.95M. Another important revenue stream is International. Understanding this composition is critical for investors evaluating how KEQU navigates market cycles within the Business Support Supplies industry.

Evaluating the bottom line, Kewaunee Scientific Corp maintains a gross margin of 29.75%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 7.31%, while the net margin is 5.17%. These profitability ratios, combined with a Return on Equity (ROE) of 13.82%, provide a clear picture of how effectively KEQU converts its operational activities into shareholder value.

In the context of the broader market, KEQU competes directly with industry leaders such as LUNG and LNSR. With a market capitalization of $104.71M, it holds a leading position in the sector. When comparing efficiency, KEQU's gross margin of 29.75% stands against LUNG's 77.97% and LNSR's 57.88%. Such benchmarking helps identify whether Kewaunee Scientific Corp is trading at a premium or discount relative to its financial performance.

Kewaunee Scientific has shown mixed financial performance. Total revenue for fiscal year 2026 was $281.99 million, a 17.3% increase from the previous year, but Q4 revenue fell by 7.5% year-over-year. The gross margin for Q4 was 29.75%, indicating some stability, but net income decreased significantly in Q4 compared to the previous year.